Insmed Plummets to 111th in Trading Volume Ranking with $698 Million Decline

On June 12, 2025, Insmed (INSM) experienced a significant decline, with its trading volume reaching $698 million, marking a 43.16% decrease from the previous day. This placed Insmed at the 111th position in terms of trading volume for the day. The stock price of Insmed dropped by 1.12%.

Insmed Incorporated recently announced the pricing of a $750 million public offering of 7,812,500 shares of its common stock at $96.00 per share. The gross proceeds from this offering, before deducting underwriting discounts and commissions, are expected to be approximately $750 million. Additionally, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock.

The company intends to use the net proceeds from this offering to fund continued research and development of brensocatib, as well as pre-commercial and, if approved, commercialization activities related to brensocatib. The funds will also support activities related to the further commercialization and development of ARIKAYCE, further research and development of treprostinil palmitil inhalation powder (TPIP), INS1201, and the Company's pre-clinical research product candidates, and for other general corporate purposes, including business expansion activities.

Goldman Sachs & Co. LLC, Leerink Partners, BofA Securities, Jefferies, and J.P. Morgan are acting as joint book-running managers for the offering. Stifel is acting as co-lead manager for the offering. The offering is expected to close on June 13, 2025, subject to the satisfaction of customary closing conditions.